TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33222923

Group type: EXPERIMENTAL
Intervention: Ekso‐GT (overground exoskeleton)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard gait training (control group)
Number of subjects: 30
Study: 36334430

Group type: EXPERIMENTAL
Intervention: Chemically protected sodium butyrate (CSB) 1,000 mg/kg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Antibiotics (enramycin 8 mg/kg and aureomycin 100 mg/kg)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 192
Study: 34185116

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 34924009

Group type: EXPERIMENTAL
Intervention: Cognitive games platform by HappyNeuron (HN)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (Non-Training group)
Number of subjects: 100
Study: 36138191

Group type: EXPERIMENTAL
Intervention: Bariatric arterial embolization (BAE)
Number of subjects: 7
Study: 33966029

Group type: EXPERIMENTAL
Intervention: qHPV (Gardasil-4, MSD)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 32699231

Group type: EXPERIMENTAL
Intervention: placebo + LSD (100 µg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5-HT2A receptor antagonist ketanserin (40 mg) + LSD (100 µg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 24
Study: 36071112

Group type: EXPERIMENTAL
Intervention: Citalopram (8 mg)
Number of subjects: 79
Study: 32673189

Group type: EXPERIMENTAL
Intervention: Narrative message featuring negative consequences of nicotine addiction
Number of subjects: 0
Study: 33989797

Group type: COMPARATOR
Intervention: PRESSURE
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BALANCE
Number of subjects: 35
Study: 32565848

Group type: EXPERIMENTAL
Intervention: Biocurcumin (BCM-95)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 37902943

Group type: EXPERIMENTAL
Intervention: IA 40 mg TCA followed by IA 0.07 mg LOR
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IA 0.07 mg LOR followed by IA 40 mg TCA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both treatment sequences
Number of subjects: 40
Study: 32070556

Group type: EXPERIMENTAL
Intervention: MIPO with percutaneous lag screw (Group-B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: MIPO without lag screw (Group-A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (Group-A and Group-B)
Number of subjects: 42
Study: 34037468

Group type: EXPERIMENTAL
Intervention: Personalized, goal-centered, and administrative electronic messages for 12 weeks
Number of subjects: 890

Group type: COMPARATOR
Intervention: Administrative messages
Number of subjects: 890
Study: 32895744

Group type: EXPERIMENTAL
Intervention: Nebulised saccharin solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 34184798

Group type: EXPERIMENTAL
Intervention: Depot buprenorphine (CAM2038 weekly for 4 weeks then monthly)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Depot buprenorphine (CAM2038)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Daily oral methadone
Number of subjects: 67
Study: 34016738

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg/d)
Number of subjects: 57
Study: 32991229

Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall prevalence of uterine leiomyoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-year incidence in the 26-30 age group
Number of subjects: 0
Study: 32535338

Group type: EXPERIMENTAL
Intervention: Play Orbit (n = 50)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Play Orbit and CSA lessons (n = 55)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (n = 34)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Complete all of Orbit
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Did not complete the game
Number of subjects: 139
Study: 36316874

Group type: EXPERIMENTAL
Intervention: Intervention (operator stood in the patient's axillary line)
Number of subjects: 44
Study: 34804266

Group type: EXPERIMENTAL
Intervention: Sensory-informed (weighted modality)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Attachment-informed (secure base priming)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control (no designated coping strategy)
Number of subjects: 272
Study: 35769196

Group type: EXPERIMENTAL
Intervention: Date seed powder (26 g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35230053

Group type: EXPERIMENTAL
Intervention: High-Dose Pindolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32235690

Group type: EXPERIMENTAL
Intervention: Steamed potato bread (raw wheat flour to cooked potato flour ratio of 3:7)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Steamed wheat bread (100% raw wheat flour)
Number of subjects: 4
Study: 36169433

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (Group B)
Number of subjects: 134

Group type: COMPARATOR
Intervention: No treatment (Group A)
Number of subjects: 134
Study: 32530765

Group type: EXPERIMENTAL
Intervention: Boost radiotherapy (36 Gy total dose) after single or tandem autologous stem-cell transplantation
Number of subjects: 323

Group type: COMPARATOR
Intervention: Single SCT with 21.6 Gy radiotherapy (no boost)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Single SCT with boost radiotherapy (36 Gy total dose) for incomplete resection
Number of subjects: 323

Group type: COMPARATOR
Intervention: Single SCT with 21.6 Gy radiotherapy (no boost) for incomplete resection
Number of subjects: 323
Study: 35504635

Group type: EXPERIMENTAL
Intervention: PMP-I (Problem Management Plus for Immigrants)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Community support services pamphlets (Control)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PMP-I
Number of subjects: 232
Study: 33529381

Group type: EXPERIMENTAL
Intervention: Flapless administration of enamel matrix derivative (EMD) as adjunct to re‐instrumentation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Re‐instrumentation without adjunctive EMD (control)
Number of subjects: 44
Study: 34083204

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorder in patients with BD
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Comorbid anxiety disorder in first-degree relatives (UR)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Smartphone-based patient-reported anxiety symptoms
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Patients with comorbid anxiety disorder
Number of subjects: 372
Study: 32150296

Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose combinations from the first stage of the trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive randomization of patients to dose combinations
Number of subjects: 0
Study: 35906011

Group type: EXPERIMENTAL
Intervention: Improved diet quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investments in school food programs
Number of subjects: 0
Study: 33594103

Group type: EXPERIMENTAL
Intervention: KNO3 (2.5% and 5%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: SiO2 (3% and 3.5%)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salicylic acid (1 mM and 2.5 mM)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5
Study: 32423920

Group type: EXPERIMENTAL
Intervention: Deltamethrin-resistant mosquitoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deltamethrin-susceptible mosquitoes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotyping of individual mosquitoes by PCR-RFLP
Number of subjects: 0
Study: 35892135

Group type: EXPERIMENTAL
Intervention: Action Observation and Motor Imagery (AO+MI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 80
Study: 33538237

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 32329780

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Venturi mask (V-mask)
Number of subjects: 171
Study: 36498561

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Partial Plantar Fasciotomy (PPF) surgery
Number of subjects: 32
Study: 32611673

Group type: EXPERIMENTAL
Intervention: Laser moxibustion
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sham laser control
Number of subjects: 392
Study: 35467939

Group type: COMPARATOR
Intervention: No reinforcement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oversewing using 3‐0 polydioxanone (PDS) suture
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oversewing using 4‐0 barbed absorbable closure device (V‐Lock)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fibrin sealant glue
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Buttress material
Number of subjects: 200
Study: 32746728

Group type: EXPERIMENTAL
Intervention: Overhead squat
Number of subjects: 12

Group type: COMPARATOR
Intervention: Forefoot standing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Back squat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Front squat
Number of subjects: 12
Study: 36043781

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg single dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 34261738

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1075
Study: 33966361

Group type: EXPERIMENTAL
Intervention: Liposomal Glutathione (L-GSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro Everolimus treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of L-GSH and Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33754332

Group type: EXPERIMENTAL
Intervention: Water exchange-assisted enteroscopy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Carbon dioxide-insufflated enteroscopy
Number of subjects: 110
Study: 32153073

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comprehensive Medical Management (CMM)
Number of subjects: 0
Study: 32265143

Group type: EXPERIMENTAL
Intervention: Optical Enhancement (OE)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combined use of targeted biopsies and random biopsies in OE group
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combined use of targeted biopsies and random biopsies in acetic acid group
Number of subjects: 154

Group type: COMPARATOR
Intervention: Image enhanced endoscopy (OE)
Number of subjects: 154
Study: 616117489

Group type: EXPERIMENTAL
Intervention: Lomerizine (10 mg per day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Methylcobalamin (1500 mug per day)
Number of subjects: 101
Study: 34550329

Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3/d
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3/d
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/d
Number of subjects: 604

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 604
Study: 34427292

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 32989916

Group type: EXPERIMENTAL
Intervention: Tertiary care multimodal treatment program
Number of subjects: 657
Study: 35444259

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 12 weeks
Number of subjects: 46
Study: 35183836

Group type: EXPERIMENTAL
Intervention: Dynamic boot immobilizer (BI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Compression sock (CS)
Number of subjects: 12
Study: 32006957

Group type: EXPERIMENTAL
Intervention: African American speakers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caucasian American speakers
Number of subjects: 0
Study: 36109819

Group type: EXPERIMENTAL
Intervention: Subcutaneous tunnelling for PICC placement
Number of subjects: 1694

Group type: COMPARATOR
Intervention: Conventional PICC placement
Number of subjects: 1694
Study: 33420498

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study: 36056374

Group type: EXPERIMENTAL
Intervention: 12-week nab-paclitaxel with gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sTIL-0 ≥ 60% (lymphocyte-predominant status)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sTIL-0 ≤ 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-week sTILs ≥ 60%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low cellularity in 3-week biopsies
Number of subjects: 0
Study: 34335943

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (arm A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bevacizumab plus chemotherapy (arm B)
Number of subjects: 104
Study: 33359062

Group type: EXPERIMENTAL
Intervention: HIV subtype C and C-related recombinants
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Unique recombination forms (URF) with genotype C for gag–pol and A1 for env
Number of subjects: 237
Study: 35240345

Group type: EXPERIMENTAL
Intervention: Informative video intervention group
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 33938290

Group type: EXPERIMENTAL
Intervention: Preferential left ventricular pacing (pLVP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard biventricular pacing
Number of subjects: 220
Study: 32570059

Group type: EXPERIMENTAL
Intervention: Laser group (LG) - photobiomodulation (PBM) using a diode laser (660 nm, 10 J/cm2, 0.28 J per point, 40 mW for intra-oral; 810 nm, 25 J/cm2, 0.7 J per point, 40 mW for extra-oral) applied three times a week during radiotherapy.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham group (SG) - sham treatment with the instrument tip sealed to prevent light passage.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Laser group (LG) - photobiomodulation (PBM)
Number of subjects: 21
Study: 35051162

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided partial release of the transverse carpal ligament using an 18-G needle
Number of subjects: 155
Study: 33295133

Group type: EXPERIMENTAL
Intervention: Group A: One dose (1 g) of IV‐TXA before skin incision + one dose (1.5 g) of IA‐TXA + single dose of IV‐TXA (1 g) for 3 h
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group B: Two doses of IV‐TXA (1 g) for 3 and 6 h
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group C: Three doses of IV‐TXA (1 g) for 3, 6, and 12 h
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control: No specific control group mentioned
Number of subjects: 300
Study: 35201791

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 113
Study: 32795317

Group type: EXPERIMENTAL
Intervention: Mapping algorithm using LTCQ-8 responses to estimate EQ-5D-5L utilities
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Multinomial response mapping model using LTCQ-8 responses
Number of subjects: 1334
Study: 35854762

Group type: EXPERIMENTAL
Intervention: Metformin combined with medroxyprogesterone acetate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate alone (control group)
Number of subjects: 120
Study: 33248904

Group type: EXPERIMENTAL
Intervention: ProFibro app
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paper book
Number of subjects: 40
Study: 32433138

Group type: EXPERIMENTAL
Intervention: 3D-printed models of sagittal, metopic, and bicoronal synostosis
Number of subjects: 44
Study: 35191291

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSG)
Number of subjects: 25
Study: 33960725

Group type: EXPERIMENTAL
Intervention: GLPG1205 10 to 800 mg (single doses)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: GLPG1205 50 mg (once daily for 14 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: GLPG1205 250 mg loading dose followed by 50 mg once daily for 13 days (open-label part)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 32386000

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg orally every night for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined group with atorvastatin and subcutaneous injection of 140 mg evolocumab every 2 weeks for 4 weeks
Number of subjects: 40
Study: 33594695

Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge (CCB) nurse‐coordinated transitional care intervention
Number of subjects: 153
Study: 33050910

Group type: EXPERIMENTAL
Intervention: SRT with concurrent systemic therapies (ST) including chemotherapy, immunotherapy, targeted therapy, and hormonotherapy.
Number of subjects: 99

Group type: COMPARATOR
Intervention: SRT alone without concurrent ST.
Number of subjects: 99
Study: 35618375

Group type: EXPERIMENTAL
Intervention: High fidelity coaching
Number of subjects: 151

Group type: COMPARATOR
Intervention: Lower fidelity coaching
Number of subjects: 151
Study: 33647518

Group type: EXPERIMENTAL
Intervention: BioBERT-based neural network classifiers
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Majority vote and label aggregation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two rule-based methods (phrase-based and section header-based)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inter-annotator agreement
Number of subjects: 50
Study: 32676679

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 2151

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2151

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2151

Group type: EXPERIMENTAL
Intervention: Post-randomisation subgroup (longer time to shock reversal)
Number of subjects: 2151

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 2151

Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 2151

Group type: EXPERIMENTAL
Intervention: Gender (male vs female)
Number of subjects: 2151
Study: 34425016

Group type: EXPERIMENTAL
Intervention: Lower oxygenation group (PaO2 of 8 kPa)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Higher oxygenation group (PaO2 of 12 kPa)
Number of subjects: 110
Study: 32188478

Group type: COMPARATOR
Intervention: PALs
Number of subjects: 600
Study: 32207735

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 31
Study: 35835210

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 33782086

Group type: EXPERIMENTAL
Intervention: Nutritional formulation containing myo-inositol, probiotics, and multiple micronutrients (intervention)
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Standard micronutrient supplement (control)
Number of subjects: 1729
Study: 32169689

Group type: EXPERIMENTAL
Intervention: Continued escitalopram treatment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Switch to bupropion (blinded control condition)
Number of subjects: 180
Study: 35675076

Group type: EXPERIMENTAL
Intervention: 10 mg of atogepant
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: 30 mg of atogepant
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: 60 mg of atogepant
Number of subjects: 902

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 902
Study: 34848313

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (HES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 70
Study: 35081832

Group type: EXPERIMENTAL
Intervention: POCUS-guided cannulation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard cannulation
Number of subjects: 13
Study: 33661911

Group type: EXPERIMENTAL
Intervention: Machine-learning analysis with radiomics features and APCT (training cohort)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Machine-learning analysis with radiomics features and APCT (validation cohort)
Number of subjects: 500
Study: 32686958

Group type: EXPERIMENTAL
Intervention: Rad-score based on four characteristic parameters (ClusterShade_AllDirection_offset4_SD, ShortRunEmphasis_angle45_offset1, Maximum3DDiameter, SurfaceVolumeRatio)
Number of subjects: 89
Study: 35274326

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg plus standard therapy (hydroxychloroquine + Kaletra®)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard therapy (hydroxychloroquine + Kaletra®)
Number of subjects: 156
Study: 33287829

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) strategy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Machine learning (ML) algorithm
Number of subjects: 206
Study: 35199483

Group type: EXPERIMENTAL
Intervention: S-flurbiprofen plaster (SFPP)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Diclofenac gel
Number of subjects: 311
Study: 33498953

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min)
Number of subjects: 41
Study: 35666889

Group type: EXPERIMENTAL
Intervention: Nondirective therapy (ND)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sudden losses (SLs) and reversals
Number of subjects: 59
Study: 35397656

Group type: EXPERIMENTAL
Intervention: Anterior and anterolateral approaches
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Anteversion angles ≥ 25°
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Inclination angles ≥ 50°
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: UHMWPE‐X and UHMWPE‐XE liners
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Cup positioning outside the Lewinnek safe zone
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Mean anteversion
Number of subjects: 372
Study: 35641950

Group type: EXPERIMENTAL
Intervention: Positive framing condition (communication training)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Negative framing condition (statistics seminar)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 192